Description
ACE-031 | ActRIIB-Fc Myostatin Inhibitor — Research Grade
ACE-031 is a recombinant fusion protein comprising the ligand-binding domain of activin receptor type IIB (ActRIIB) fused to human IgG1-Fc. It acts as a decoy receptor, capturing myostatin, GDF-11, GDF-8, and activins before they can bind endogenous ActRIIB on muscle fibres.
Mechanism of Action
- Myostatin sequestration — binds and neutralises myostatin (GDF-8), a potent inhibitor of skeletal muscle growth
- GDF-11 inhibition — also captures GDF-11 and activins A/B, broadening its anti-catabolic scope
- ActRIIB decoy — prevents endogenous ActRIIB signalling (Smad 2/3 pathway) which promotes muscle protein catabolism
- Muscle fibre hypertrophy — Phase I/II data in healthy postmenopausal women showed 3-5% lean mass increase after single dose
Research Areas
ACE-031 is studied in Duchenne muscular dystrophy (Phase II), sarcopenia, cancer cachexia, and muscle wasting disease. It remains a key research tool in myostatin biology.
For Research Use Only. Rainbow Peptide supplies ACE-031 exclusively for in vitro and laboratory research purposes. Not for human or veterinary use.
Dr. R. Becker –
ACE-031 (ActRIIB-Fc) for our myostatin pathway and muscle atrophy research. Purity confirmed >98% by HPLC. Myostatin binding inhibition in our cell-based assay was as expected. COA was the most thorough we’ve received.
M. Johanssen –
Second order of ACE-031. Quality consistent with first lot. Our GDF-8 inhibition model showed reproducible results. COA detailed. Appropriate cold-chain delivery. Highly recommend for myostatin research.
O. Emeka –
ACE-031 for our sarcopenia research. Purity >98%. Dissolved as expected. COA comprehensive. The ActRIIB inhibition response in our assay aligned with published data. Good value research-grade product.